| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 211.1MM | - |
| Operating Income | 343K | -100% |
| Operating Expenses | 210.8MM | - |
| Net Income | -36.2MM | -79% |
| R&D | 141MM | +8% |
| G&A | 65.8MM | +38% |
| Amortization | 600K | - |
| Interest Expense | 23.5MM | +16% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2024 Results Key Financial Results Revenue: US$211.1m (up by US$209.3m...
BBOT will advance the development of three initial cancer treatment programmes.
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abst
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat p
The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s rest
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demonstrate that targeting near-complete transthyretin (TTR) stabilization with acoramidis may enable cardiac remodeling and functional recovery in patients with ATTR-CM - These results are the first prospective, longitudinal evaluation of cardiac structure and function by CMR imaging in a
Let’s talk about stock picking. It’s a bit like going to an orchard: if you get there too late, the low-hanging fruit is all gone, and you’ll have to work harder to find the best pieces. Orcharders have ladders and pruning hooks to make the job easier; retail investors can turn to the Smart Score. The Smart Score uses a combination of AI and natural language processing, through an algorithm by TipRanks, to gather and collate the mountain of raw data tossed up by the regular daily activity of the